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A mysterious disorder is killing more than half a million 
patients around the world each year. Th  is disorder is 
associated with sudden onset of profound impairment of 
kidney function and its exact cause is unclear and treat-
ment is unsatisfactory. Th  e condition primarily aﬀ  ects 
acutely ill and injured patients and dispro  por  tionably 
aﬀ  ects the elderly. Many of those that survive remain 
with permanent kidney failure.
Th  e term acute kidney injury (AKI) was coined by 
William MacNider in 1918 in reference to acute mercury 
poisoning, but only became a preferred term since 2004 
when it was deﬁ   ned using widely accepted consensus 
criteria known as Risk-Injury-Failure-Loss-End stage 
kidney disease (RIFLE) [1]. AKI replaced the term acute 
renal failure in part because of the recognition that acute 
impairment in renal function, even when relatively mild 
and far less than frank failure (only an increase in serum 
creatinine of 0.3 mg/dl or 6 hours of oliguria), is 
associated with worse clinical outcomes. Criteria for AKI 
were therefore set at small changes in serum creatinine or 
urine output, and when these criteria were applied to 
intensive care [2], hospital or even population-based [3] 
cohorts two observations were made. First, AKI is 
common, occurring in as many as two-thirds of ICU 
patients [2] and about 2,100 per million population [3], 
and is associated with dramatic reductions in survival 
[2-3].
As more information becomes available on this illness, 
it is clear that much of what we think we know is 
questionable. For example, dehydration causes the kidney 
to concentrate the urine but when dehydration is 
extreme, our kidneys can no longer excrete the solute 
load produced by our bodies and we develop biochemical 
evidence of impaired kidney function. We refer to this 
state as pre-renal because it is produced by abnormalities 
‘upstream’ of the kidney. A similar situation arises when 
there is insuﬃ     cient circulating blood volume due to 
hemorrhage or when the heart fails to deliver adequate 
cardiac output. Indeed, even a thrombosis of the renal 
artery would be classiﬁ  ed as pre-renal. When the pre-
renal state is very transient and/or mild, and when it is 
occurring in the setting of normal baseline renal function, 
it may appear to be well tolerated. However, emerging 
evidence suggests that the pre-renal state is precarious. 
First, it may potentiate renal toxicity from radiocontrast 
or other nephrotoxins. Second, renal impairment may 
lead to volume overload, acid-base and electrolyte 
imbalance, immune dysfunction, coagulation abnor  mali-
ties, abnormal drug elimination and direct eﬀ  ects on the 
function of various organs [4]. Indeed, renal impairment 
results in multiple organ failure. Finally, when severe or 
prolonged, or perhaps even when mild and transient, but 
in an already compromised kidney, the pre-renal state 
can lead to direct kidney damage.
Another area of controversy concerns our under-
standing of the pathogenesis of AKI [4]. Epidemiologic 
evidence suggests that AKI is not a single disease but a 
syndrome comprising multiple, often coexisting etiolo-
gies [5]. Th  e most common forms of AKI appear to be 
non-ischemic [6,7] and arise in settings such as sepsis 
and heart failure. Early AKI may be purely functional and 
reversible but soon gives way to tissue injury and a 
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changes. Furthermore, the kidney may be an innocent 
bystander injured by the ‘toxic waste’ that it ﬁ  lters from 
the blood in the setting of remote tissue injury and 
infection. Cytokines, free radicals, microvesicles and 
other damage-associated molecular patterns may initiate 
AKI, and ‘maladaptive repair’ mechanisms [8] may cause 
further damage, particularly in the most susceptible 
patients, such as the elderly and those with chronic 
kidney disease.
Such a multifaceted disease process has been diﬃ   cult 
to study both in animals and in humans. Th  erapies  that 
work in speciﬁ  c experimental models may have little or 
no eﬃ   cacy when translated into the clinical realm, where 
overlapping etiologies is the rule. Th   ere may be no ‘magic 
bullet’ for AKI. Instead, it may be possible to develop a 
‘magic shield’ to attenuate the many diﬀ  erent  inciting 
factors and to produce eﬀ  ective countermeasures that 
facilitate resolution of injury and promote recovery of 
function. Novel biomarkers for early detection of AKI 
and for predicting the course of disease in humans are 
being developed and we will thus soon have better ways 
to apply the right therapies to the right patients.
Finally, we have learned a great deal about renal 
support. Th  ough our recent trials have been negative, 
they have been successful and they have generated 
impor  tant hypotheses about patient selection and timing 
of initiation. Renal replacement therapy is being delivered 
earlier and to more severely ill patients than ever before. 
Th  ere is some evidence that survival for patients with 
AKI is improving, though it is still quite poor in critically 
ill patients. Renal support may well be the bridge to 
recovery but innovation is lagging - we have seen little 
change in the way we provide support over the past three 
decades. If we are to expect better outcomes, we will 
need to develop better therapies.
Advanced technologies in the forms of increased 
hemo ﬁ  ltration volumes, higher cutoﬀ   membranes, plasma 
ﬁ   ltration and adsorption are potential solutions to 
improve renal support. Technologies for extracorporeal 
removal of larger microbial toxins, such as endotoxin, are 
also becoming available. Finally, it must be recognized 
that AKI is usually part of a multi-organ failure syndrome 
and extracorporeal support may also target ﬂ  uid overload 
and heart failure, extracorporeal CO2 removal for 
combined kidney and lung support, albumin dialysis for 
liver support and other techniques uniﬁ   ed under the 
umbrella of MOST (multiple organ support therapy) [9]. 
Such therapies aim to improve organ function and 
decrease severity of organ damage.
In summary, the advances in AKI epidemiology that 
have been seen in the past decade have opened new 
vistas that we can explore for new diagnostic makers and 
new therapies. However, new challenges are also 
appa  rent. We need to better understand why AKI occurs 
and to develop new paradigms to treat it. Business as 
usual will result in the usual outcomes and as survival 
from other forms of vital organ failure improve [10], AKI 
has lagged behind. It’s time we took up the challenge to 
set a new course. Th   e 2011 Brussels Roundtable seeks to 
begin this process.
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